Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Sutimlimab boosts hemoglobin, quality of life in cold agglutinin disease

Publish date:: December 12, 2019

Key clinical point: Blocking the complement pathway is a novel method for treating at least one form of hemolytic anemia.

Major finding: Hemoglobin levels increased by a mean of 2.6 g/dL.

Study details: An open-label, phase 3 trial in 24 patients with cold agglutinin disease, a rare autoimmune hemolytic anemia.

Disclosures: The study was supported by Sanofi. Dr. Röth reported financial relationships with Sanofi and other companies.

Citation:

Röth A et al. ASH 2019, Abstract LBA-2.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Anemia

Emotions, worse attention linked to pain-related health care use SCD,

Oxidatative stress-related genetic variant tied to stroke risk in sickle cell patients,

Genetic variants may predict stroke in some adult SCD populations,

Severe COVID-19 may lower hemoglobin levels,

Low plasma sodium levels can predict complications in acute painful episodes of SCD,

All Specialties